{"protocolSection": {"identificationModule": {"nctId": "NCT01603940", "orgStudyIdInfo": {"id": "CONTROL STUDY"}, "organization": {"fullName": "Hospital Universitario Pedro Ernesto", "class": "OTHER"}, "briefTitle": "Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine", "officialTitle": "Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.", "acronym": "CONTROL"}, "statusModule": {"statusVerifiedDate": "2015-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-05"}, "primaryCompletionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-05-20", "studyFirstSubmitQcDate": "2012-05-22", "studyFirstPostDateStruct": {"date": "2012-05-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-08-18", "resultsFirstSubmitQcDate": "2015-10-09", "resultsFirstPostDateStruct": {"date": "2015-11-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-12-29", "lastUpdatePostDateStruct": {"date": "2016-02-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Ronaldo Altenburg Odebrecht Curi Gismondi", "investigatorTitle": "Investigator. Medical Doctor. Master of Sciences.", "investigatorAffiliation": "Hospital Universitario Pedro Ernesto"}, "leadSponsor": {"name": "Hospital Universitario Pedro Ernesto", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare losartan and benazepril in diabetic patients whose high blood pressure is not controlled by amlodipine and its relationship to statin current use.", "detailedDescription": "Hypertension and diabetes mellitus are important risk factors for cardiovascular morbidity and mortality. Endothelial dysfunction and vascular rigidity are two pathophysiological mechanisms that may explain this relationship. Recent publications showed that both ACEi (angiotensin-converting enzyme inhibitor-induced) and ARB (angiotensin receptor blocker) were capable of improving vascular stiffness and endothelial function, and that these effects occurred despite blood pressure reduction.\n\nThis study main objective is to assess if ARB (losartan) effects are different from ACEi (benazepril) in endothelial function in patients with diabetes mellitus type 2 and blood pressure not controlled by amlodipine and its relationship to statin current use.\n\nSecondary analysis of vascular stiffness will be measured by pulse wave velocity and augmentation index. Echocardiographic parameters, such as indexes of diastolic function, will also be measured."}, "conditionsModule": {"conditions": ["Hypertension", "Diabetes Mellitus"], "keywords": ["Hypertension", "Diabetes Mellitus", "Vascular stiffness", "Endothelial function"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Losartan", "type": "ACTIVE_COMPARATOR", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.", "interventionNames": ["Drug: Losartan"]}, {"label": "Benazepril", "type": "ACTIVE_COMPARATOR", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.", "interventionNames": ["Drug: Benazepril"]}], "interventions": [{"type": "DRUG", "name": "Benazepril", "description": "Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.", "armGroupLabels": ["Benazepril"], "otherNames": ["Lotensin", "0078-0447-05"]}, {"type": "DRUG", "name": "Losartan", "description": "Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.", "armGroupLabels": ["Losartan"], "otherNames": ["Cozaar", "0006-0951-54"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Endothelial Function", "description": "Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use.", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Vascular Stiffness", "description": "Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril).", "timeFrame": "12 weeks."}, {"measure": "Systolic Blood Pressure", "description": "Compare both groups effects on systolic blood pressure.", "timeFrame": "12 weeks"}, {"measure": "Diastolic Blood Pressure", "description": "Compare both group effects on diastolic blood pressure.", "timeFrame": "12 weeks"}, {"measure": "Vascular Stiffness by Augmentation Index", "description": "Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups.", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Ambulatorial patients with age between 40 and 70 years-old.\n* Systemic arterial hypertension previously diagnosed and in use of two or less anti-hypertensive drugs in the preceding 4 weeks.\n* Type 2 diabetes mellitus in use of oral medication that were not changed in the preceding 4 weeks. Glycated hemoglobin A1c less than 9.0%.\n* Accepted the consent form.\n\nExclusion Criteria:\n\n* Office systolic blood pressure equal or more than 180 mmHg, with or without treatment\n* Office diastolic blood pressure equal or more than 110 mmHg, with or without treatment\n* Evidences of a secondary cause for hypertension\n* Glycated hemoglobin A1c \\> 9.0%\n* Insulin therapy\n* Chronic kidney disease stage 4 or 5 or in dialysis\n* Advanced target organ lesion, obtained by history or additional exams, and defined by: previous myocardial infarction, heart failure with ejection fraction less than 40%, cerebral vascular accident (ischemic or hemorrhagic), peripheral vascular disease (claudication or doppler with obstruction \\> 50% of vascular lumen), retinopathy with visual loss, symptomatic neuropathy.\n* Cardiac arrhythmias, except for ectopic beats\n* Any clinical or disabling condition that, in the opinion of the investigators, may confound or prejudice study results.\n* Severe mitral regurgitation.\n* Women in fertile age without contraceptive methods in use.\n* Breastfeeding women.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Wille Oigman, MD, DSc.", "affiliation": "Hospital Universitario Pedro Ernesto", "role": "STUDY_CHAIR"}, {"name": "Mario F Neves, MD, DSc.", "affiliation": "Hospital Universitario Pedro Ernesto", "role": "STUDY_DIRECTOR"}, {"name": "Ronaldo A Gismondi, MD, MSc.", "affiliation": "Hospital Universitario Pedro Ernesto", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital Universitario Pedro Ernesto", "city": "Rio de Janeiro", "state": "RJ", "zip": "20551030", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}]}, "referencesModule": {"references": [{"pmid": "26465872", "type": "DERIVED", "citation": "Gismondi RA, Bedirian R, Pozzobon CR, Ladeira MC, Oigman W, Neves MF. Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics. Arq Bras Cardiol. 2015 Dec;105(6):597-605. doi: 10.5935/abc.20150123. Epub 2015 Oct 2."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "FG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "BG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "30"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57", "lowerLimit": "53", "upperLimit": "63"}, {"groupId": "BG001", "value": "57", "lowerLimit": "52", "upperLimit": "62"}, {"groupId": "BG002", "value": "57", "lowerLimit": "52", "upperLimit": "63"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "19"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "30"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Endothelial Function", "description": "Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage of maximal vasodilation", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "OG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.4", "lowerLimit": "7.7", "upperLimit": "13.5"}, {"groupId": "OG001", "value": "8.8", "lowerLimit": "6.9", "upperLimit": "11.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.616", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Vascular Stiffness", "description": "Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "m/s", "timeFrame": "12 weeks.", "groups": [{"id": "OG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "OG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.5", "lowerLimit": "7", "upperLimit": "9.7"}, {"groupId": "OG001", "value": "8.5", "lowerLimit": "7.8", "upperLimit": "9.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.28", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure", "description": "Compare both groups effects on systolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mmHg", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "OG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "134", "lowerLimit": "127", "upperLimit": "143"}, {"groupId": "OG001", "value": "139", "lowerLimit": "130", "upperLimit": "154"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.618", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure", "description": "Compare both group effects on diastolic blood pressure.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mmHg", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "OG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80", "lowerLimit": "69", "upperLimit": "84"}, {"groupId": "OG001", "value": "82", "lowerLimit": "74", "upperLimit": "89"}]}]}]}, {"type": "SECONDARY", "title": "Vascular Stiffness by Augmentation Index", "description": "Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage of augmentation pressure", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks."}, {"id": "OG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28", "lowerLimit": "21", "upperLimit": "37"}, {"groupId": "OG001", "value": "35", "lowerLimit": "26", "upperLimit": "41"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Losartan", "description": "This group will receive 100 mg of losartan per day. Amlodipine will be maintained.\n\nLosartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 2, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Benazepril", "description": "This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.\n\nBenazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 1, "otherNumAtRisk": 14}], "otherEvents": [{"term": "Edema", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "edema", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Not severe edema in losartan group.", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "cough", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Cough due to benazepril (ACEi: angiotensin-converting enzyme inhibitor-induced)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Ronaldo Altenburg Gismondi, MD, PhD", "organization": "Hospital Universitario Pedro Ernesto (UERJ)", "email": "ronaldogismondi@gmail.com", "phone": "+5521996092383"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "C000044946", "term": "Benazepril"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "relevance": "LOW"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M223594", "name": "Benazepril", "asFound": "Iliac crest", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}